The $30M cash infusion and HSR clearance significantly reduce deal risk and improve the pro forma balance sheet ahead of the Treeline merger. Monitor the stockholder vote and any competing bids; the merger is on track for year-end 2026 close.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 28 $0.7947entry
- T+1 · 4mo ago +9.97%α +11.50% · $0.8739
- T+5 · 4mo ago +9.00%α +6.73% · $0.8662
- T+20 · 3mo ago −18.21%α −21.59% · $0.6500
- T+60 · 27d ago −18.21%α −22.56% · $0.6500
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Standard BioTools announced the sale of its Mass Cytometry business to Multiplex Bio for up to $10M, received ~$30M from Illumina to buy out earnout/royalty obligations, and secured early HSR termination for its pending merger with Treeline Biosciences. These actions strengthen the balance sheet, reduce contingent liabilities, and de-risk the Treeline merger, which is expected to close by year-end 2026.
Key Financial Metrics
Key Facts
- Sale of Mass Cytometry business to Multiplex Bio for up to $10 million (seller's note + milestone payment)
- Received approximately $30 million from Illumina to buy out 2026 earnout and all future royalty payments related to the SomaLogic acquisition
- U.S. FTC granted early termination of HSR waiting period for the Treeline merger
- Treeline merger and Mass Cytometry sale expected to close by end of 2026, subject to stockholder approval and customary conditions
- Standard BioTools will provide Multiplex Bio with a working capital loan of up to $10 million at closing
Financial Impact
~$30M cash received from Illumina buyout; up to $10M from Mass Cytometry sale (seller's note + milestone); up to $10M working capital loan to Multiplex Bio
Risk Factors
- Stockholder approval required for both the Mass Cytometry sale and the Treeline merger
- Customary closing conditions may delay or prevent the transactions
- Potential for competing acquisition proposals or termination of the Treeline merger
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3334170 |
Track record
23 reports on LAB
6 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +17.95% at T+20 after the Feb 24, 2026 report. 8 of 8 went positive at some point.
Filters
- Nov 16, 2026today 425 Neutral 4/10 Entry price pending
- Nov 16, 2026today 8-K Neutral 3/10 Entry price pending
- Nov 3, 202613d ago 425 Neutral 3/10 Entry $0.6108 to $0.6160 Now $0.6200 +1.51% ▲ +0.85% −0.80% vs SPY
- Nov 3, 202613d ago 8-K Neutral 4/10 Entry $0.6108 to $0.6160 Now $0.6200 +1.51% ▲ +0.85% −0.80% vs SPY
- Nov 3, 202613d ago Press Release Neutral 3/10 Entry $0.6108 to $0.6160 Now $0.6200 +1.51% ▲ +0.85% −0.80% vs SPY
- Oct 22, 202626d ago EFFECT Neutral 4/10 Entry $0.6400 to $0.6056 Now $0.6200 −3.12% ▼ −5.38% −4.85% vs SPY
- Oct 21, 202626d ago S-4/A Bearish 7/10 Entry $0.6500 to $0.6400 Now $0.6200 +4.62% ▲ +1.54% +0.36% vs SPY
- Oct 9, 20265w ago S-4/A Neutral 6/10 Entry $0.6578 to $0.6589 Now $0.6200 −5.75% ▲ +0.17% +0.18% vs SPY
- Oct 5, 20266w ago 425 Neutral 5/10 Entry $0.7220 to $0.6787 Now $0.6200 −14.13% ▼ −6.00% −5.76% vs SPY
- Oct 5, 20266w ago 8-K Neutral 4/10 Entry $0.7220 to $0.6787 Now $0.6200 −14.13% ▼ −6.00% −5.76% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers